Kodiak Sciences Inc. (KOD)
Kodiak Sciences develops drug treatments for retinal eye diseases, with its lead candidate still in clinical trials. It last closed at $96.80 on Nov 17, down 3.90% on the day. The average 12-month price target from 4 analysts is $114.25 (+18.0% from the last close), with a high of $150.00 and a low of $36.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in KOD, 71% of them bullish and 29% bearish. In the past 30 days there were 1 dark pool print totaling $1.0M, the largest $1.0M.
Key Stats
Last 12 monthsNot reported for this period.
From KOD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on KOD in the past 90 days. The average target is $114.25, with a high of $150.00 and a low of $36.00, compared with the last close of $96.80.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | UBS | Target raised | Buy | $120 → $150 |
| Oct 12 | HC Wainwright & Co. | Target raised | Buy | $96 → $126 |
| Sep 28 | LifeSci Capital | Maintained | Buy | $145 |
| Sep 28 | UBS | Maintained | Buy | $120 |
| Sep 28 | HC Wainwright & Co. | Target raised | Buy | $58 → $96 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 52% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the Pivot S1 at $92.84, and the nearest resistance the 20 day average at $98.27.
| RSI (14) | 51.87 | Middle of its range | Neutral |
| MACD | 6.33 | Below its signal line | Bearish |
| Stochastic | 56.5 | Middle of its range | Neutral |
| ADX (14) | 30.9 | Trending up | |
| Williams %R | -71.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 3.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.1% | Change over 10 sessions | Bearish |
| ATR (14) | $7.07 | Typical daily range, 7.3% of price |
| RSI (14) | 67.79 | Strong, overbought above 70 | Neutral |
| MACD | 17.87 | Above its signal line | Bullish |
| Stochastic | 90.9 | Near the top of its range | Overbought |
| ADX (14) | 38.7 | Trending up | |
| Williams %R | -19.2 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 96.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +194.3% | Change over 10 sessions | Bullish |
| ATR (14) | $12.12 | Typical daily range, 12.5% of price |
What happened before
See how KOD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KOD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in KOD in the last 90 days.
Dark Pool
30DKOD Institutional Ownership
Full report →- ●110 buying vs 113 selling
- ●Held by funds -0.2 pts
- ▲Funds holding +17
- ●Superinvestors: 2 added, 2 cut
- ▼Put/call 0.33 to 0.70
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 217 | 200 | +8.5% |
| In funds' top 10 | 10 | 7 | +42.9% |
| Held by funds | 92.3% | 92.5% | −0.2 pts |
| New / increased | 51 / 59 | 35 / 81 | −5.2% |
| Reduced / sold out | 79 / 34 | 55 / 24 | +43.0% |
| Put/call ratio | 0.70 | 0.33 | +107.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KOD is in one of them and how their past KOD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KOD in an article yet. Here's the latest on the wider market.
KOD Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Christopher JacobsR · NY | Sell | $1K – $15K | Nov 8, 2022 | Dec 12, 2022 | 34 d |
| Christopher JacobsR · NY | Buy | $1K – $15K | Jul 18, 2022 | Sep 9, 2022 | 53 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Kodiak Sciences
Kodiak Sciences is a biotechnology company based in Palo Alto, California, that develops drugs for diseases of the retina, the light sensitive tissue at the back of the eye. Its candidates are built on its Antibody Biopolymer Conjugate platform, which is designed to keep drugs active in the eye for longer. The lead candidate, tarcocimab, is in Phase 3 trials for conditions such as wet macular degeneration and diabetic retinopathy and has not yet been approved for sale.
- Headquarters
- Palo Alto, CA
- Website
- kodiak.com ↗




